

1

2

3

4 Herpes simplex virus 1 inhibits phosphorylation of RNA polymerase II

5

CTD serine-7

6

7 Adam W. Whisnant¹, Oliver Dyck Dionisi¹, Arnhild Grothey¹, Julia M. Rappold¹, Ana Luiza

8

Marante¹, Sharada S. Subramanian¹, Lars Dölken^{1*}

9

10

11

12

13

14 ¹ Institute for Virology and Immunobiology, Julius-Maximilians-University Würzburg,

15 Versbacher Straße 7, 97078, Würzburg, Germany

16

17 *Corresponding Author

18 Email: lars.doelken@uni-wuerzburg.de (LD)

19

20 **Key words:** Herpes simplex virus 1; RNA polymerase II; C-terminal domain; phosphorylation;
21 regulation of transcription

22

23 **Abstract**

24

25 Transcriptional activity of RNA polymerase II (Pol II) is orchestrated by post-

26 translational modifications of the C-terminal domain (CTD) of the largest Pol II subunit, RPB1.

27 Herpes Simplex Virus type 1 (HSV-1) usurps the cellular transcriptional machinery during lytic

28 infection to efficiently express viral mRNA and shut down host gene expression. The viral

29 immediate-early protein ICP22 interferes with serine 2 phosphorylation (pS2) of the Pol II CTD

30 by targeting CDK9. The functional implications of this are poorly understood. Here, we report

31 that HSV-1 also induces a global loss of serine 7 phosphorylation (pS7). This effect was

32 dependent on the expression of the two viral immediate-early proteins, ICP22 and ICP27.

33 While lytic HSV-1 infection results in efficient Pol II degradation late in infection, we show that

34 pS2/S7 loss precedes the drop in Pol II level. Interestingly, mutation of the RPB1

35 polyubiquitination site mutation K1268, which prevents proteasomal RPB1 degradation

36 during transcription-coupled DNA repair, displayed loss of pS2/S7 but retained much higher

37 overall RPB1 protein levels even at late times of infection, indicating that this pathway

38 mediates bulk Pol II protein loss late in infection but is not involved in early CTD dysregulation.

39 Using α -amanitin-resistant CTD mutants, we observed differential requirements for Ser2 and

40 Ser7 for production of viral proteins, with Ser2 facilitating viral immediate-early gene

41 expression and Ser7 appearing dispensable. Despite dysregulation of CTD phosphorylation

42 and different requirements for Ser2/7, all CTD modifications tested could be visualized in viral

43 replication compartments by immunofluorescence. These data expand the known means that

44 HSV-1 employs to create pro-viral transcriptional environments at the expense of host

45 responses.

46

47 **Introduction**

48 Herpes simplex virus type 1 (HSV-1) is a large, double-stranded DNA virus present in
49 nearly two-thirds of the global population that is the causative agent of the common cold-
50 sore as well as severe skin lesions, life-threatening neonatal encephalitis, and a leading cause
51 of infectious blindness (1). HSV-1 is a paradigm for a virus which induces a profound host shut-
52 off during productive infection by targeting multiple steps of RNA metabolism.

53 RNA Polymerase (Pol) II is the complex responsible for transcription of all mRNA and
54 several non-coding RNAs. In HSV-1 infection, the virus hijacks Pol II for the transcription of all
55 viral RNAs. Pol II is a multi-subunit complex with the most dynamic regulatory events
56 occurring on the C-terminal domain (CTD) of the largest subunit, RPB1. The RPB1 CTD consists
57 of heptapeptide repeats of the evolutionarily consensus sequence tyrosine-serine-proline-
58 threonine-serine-proline-serine (Y1-S2-P3-T4-S5-P6-S7) (2). Several non-consensus
59 heptapeptide repeats, particularly with variations in the seventh amino acid position, are
60 enriched in the more distal of the 52 mammalian CTD repeats. Each non-proline residue
61 serves as a site of phosphorylation that together help coordinate every step in transcription,
62 with numerous additional post-translational modifications having been described in both the
63 CTD and other regions of RPB1 (3).

64 Within hours of entering a cell, HSV-1 globally inhibits multiple Pol II processes on host
65 genes such as promoter clearance (4,5), promoter-proximal pausing (6,7), and
66 polyadenylation (8) while preserving these functions on viral genes. This selective
67 permissiveness has been attributed to different mechanisms including bulk redirection of
68 DNA-binding proteins to nucleosome-free viral DNA (5,9) to regulation of specific activities
69 such as mRNA 3'-end formation by the Cleavage and Polyadenylation Specificity Factor (CPSF).

70 Via its interaction with CPSF, the HSV-1 immediate early protein ICP27 induces the assembly
71 of a dead-end 3' processing complex, blocking mRNA cleavage. However, 3'-end processing
72 of viral (and a subset of host) transcripts is rescued by the RNA sequence-dependent
73 binding/activator activity of the viral ICP27 protein (10). The viral protein ICP22 has also been
74 shown to interact with Cyclin-dependent kinase 9 (CDK9) (11,12) and lead to a decrease of
75 phosphorylated CTD Ser2, regarded as a positive marker for transcriptional elongation (13).

76 Pol II activity is also tightly regulated under conditions of abiotic stress. For instance,
77 a failure of transcription termination has been shown under conditions of hypoxia (14); heat,
78 osmotic, and oxidative stress (15–18); as well as in renal carcinoma (19). Under these
79 conditions, the normal 3' ends of mRNA are not formed and polymerases transcribe
80 thousands of additional bases downstream of normal termination sites; termed disruption of
81 transcription termination (DoTT), downstream of gene (DoG) transcription, or read-through
82 of polyadenylation (polyA) sites / polyA read-through. Distinguishing which processes are
83 directly regulated by viral proteins and which are disrupted by cellular stress responses
84 becomes imperative to understand transcription during infection.

85 In this study, we sought to determine HSV-1-induced dysregulation of Pol II CTD
86 modifications and their functional consequences in relation to other stressors. Besides the
87 well-described loss of Ser2 phosphorylation (pS2), we report that HSV-1 infection of primary
88 human fibroblasts also resulted in a global loss of Ser7 phosphorylation (pS7) by 8h post-
89 infection (p.i.), which was not observed in cellular stress responses. Expression of the two
90 viral immediate-early genes ICP22 and ICP27 was necessary to induce loss of pS7 and we
91 provide additional evidence that loss of CTD hyperphosphorylation is separate from bulk RPB1
92 degradation. Though phosphorylation of both residues is reduced in infection, alanine
93 substitution of Ser7 had no visible impact on viral gene expression while Ser2 substitution

94 was detrimental. Despite Ser7 being dispensable for viral gene expression, its
95 phosphorylation, as well as every other CTD modification examined, could be visualized in
96 viral replication compartments in primary cells. These findings expand the known means of
97 transcriptional regulation by a major human pathogen.

98

99 **Results**

100 **Quantification of CTD Modifications During Conditions of polyA**

101 **Read-through**

102 Considerable overlap exists between genes exhibiting defective polyadenylation
103 during different conditions of osmotic or heat stress and herpes simplex virus infection (20).
104 As transcriptional termination is coordinated in part by CTD phosphorylation, we first
105 determined whether a common disruption of RPB1 modifications occurs under conditions of
106 heat stress (44°C, 2 hours [h]), HSV-1 infection (strain 17syn+, MOI=10, 8h), osmotic stress
107 (80mM KCl, 1h) or oxidative stress induced by 0.5mM sodium arsenite for 1h in primary
108 human foreskin fibroblasts. Timepoints for each condition were based on use in previous
109 studies. Both heat stress and HSV-1 infection induced accumulation of intermediately
110 phosphorylated RPB1 as seen by relative migration in SDS-PAGE (Pol Ili, Fig 1A). While all
111 phospho-serine signals were strongly enriched on hyperphosphorylated Pol II (Ilo), the signals
112 of Y1 and T4 phosphorylation and K7 di/tri-methylation more closely correlated to the relative
113 abundance of the different migrating forms of RPB1 in each sample. Interestingly, the
114 phospho-serine signals for heat stress and HSV-1 infection migrated below the
115 hyperphosphorylated Ilo signals in mock samples, but remained above the predominate Ili
116 signal for total RPB1 (see E1Z3G in green in S1A Fig).

117

118 **Fig 1. Western blot quantification of RPB1 CTD modifications in primary human fibroblasts**
119 **during conditions of polyA-site read-through.** (A) Human foreskin fibroblasts were subjected
120 to heat (44°C, 2h), HSV-1 infection (strain 17syn+, MOI 10, 8h), osmotic (80mM KCl, 1h), and
121 oxidative (0.5mM NaAsO₂, 1h) stress and total protein harvested at the end of the stress
122 period. Samples were resolved by SDS-PAGE and probed for levels of RPB1, its CTD
123 modifications, and vinculin as a housekeeping control. Signal for each CTD modification was
124 measured, normalized to the signal for total RPB1 on the same blot, and plotted relative to
125 levels in untreated cells. (B) Mean values of three biological replicates with standard
126 deviations are plotted. Statistically significant differences to mock are indicated as * $p < 0.05$,
127 ** $p < 0.01$.

128

129 Given the various migration patterns across all samples, we thus quantified signals for
130 CTD modifications across the entire range of RPB1 bands and normalized to total RPB1 signals
131 on the same blot. For all stress conditions, a slight (20-30% on average) reduction in
132 tyrosine 1 phosphorylation (pT1) was observed relative to mock (Fig 1B). Surprisingly,
133 threonine 4 phosphorylation (pT4), which predominately accumulates around transcription
134 termination sites and is involved in 3'-end formation (21,22), remained unaffected in all
135 conditions; as did serine 5 phosphorylation (pS5) and K7 di/tri-methylation levels (K7me).
136 HSV-1 infection was the only condition observed to heavily impact CTD modifications, causing
137 a ~70% reduction in pS2, as previously described, and a ~50% loss of serine 7 phosphorylation
138 (pS7).

139 As previous studies have shown binding of monoclonal antibodies to the CTD can be
140 affected by the identity and phosphorylation of nearby amino acids (23–26), we tested a
141 panel of different CTD phospho-serine antibodies for each serine residue on the same
142 samples. The data for CTD phospho-serines in Fig 1 are for selected antibodies whose epitope
143 biases have been evaluated by in other studies (23,25), with results for all antibodies in S1
144 Fig. Of five antibodies tested for pS2, all showed a reduction of pS2 in HSV-1 infection, while
145 three antibodies showed a ~2-fold reduction for heat and two for salt stress (S1A Fig).
146 Previous studies have observed similar gel migration shifts after heat shock in mammalian
147 and *Drosophila* cells (27–29), with a decrease of pS2 and pS5 reported in mouse cells (30).
148 One of three antibodies showed increases of pS5 levels for heat stress and oxidative stress,
149 while one of two antibodies showed a reduction of pS7 in all conditions (S1 Fig). Overall,
150 these data indicate that there that HSV-1 causes a loss of two major CTD modifications while
151 there is no major CTD modification indicative of general stress responses beyond a slight
152 reduction of pY1. Dephosphorylation of Y1 is directly involved in recruiting termination
153 factors in yeast (31), and mammalian RPB1 mutants where the distal 3/4 of Y1's are
154 substituted for phenylalanine also exhibit termination defects (32). However, it remains
155 unclear whether a ~20% global reduction in pY1 would be sufficient to recapitulate this
156 phenotype during cellular stress.

157

158 **Loss of CTD serine 7 phosphorylation in HSV-1 infection is due to** 159 **expression of ICP22 and ICP27**

160 The loss of pS2 during HSV-1 infection has been linked to inhibition of CDK9 by the
161 viral immediate-early (IE) protein ICP22 (11). As CDK9 can also phosphorylate Ser7 (3), we

162 investigated the role of ICP22 and other viral gene products in the loss of pS7. A time course
163 of infection, with and without the DNA replication inhibitor phosphonoacetic acid (PAA) to
164 prevent viral late gene expression, demonstrated that viral late gene products are not
165 required for the observed pS7 loss (Fig 2A,B), with a steady decrease beginning at 4h p.i. To
166 specifically test immediate-early (IE) genes, a cycloheximide reversal assay was performed. In
167 this assay, cells are infected and then treated with cycloheximide to allow transcription – but
168 not translation – of the five viral IE genes, which do not require synthesis of new viral proteins
169 for expression. After 4h, cycloheximide was removed and replaced with actinomycin D for an
170 additional 8h to allow translation of the accumulated viral IE mRNA but prevent transcription
171 of early and late genes. In these conditions however, a noticeable decrease in all forms of Pol
172 II due to degradation was observed (S2A Fig). This is in line with previous reports using
173 actinomycin D suggesting that the normal virally induced CTD modifications or even RPB1
174 stability require ongoing transcription (33).

175

176 **Fig 2. Loss of CTD serine 7 phosphorylation in HSV-1 infection requires immediate-early**
177 **proteins ICP22 and ICP27.** (A) Human foreskin fibroblasts (HFF) were infected with HSV-1
178 17syn+ with and without DNA replication inhibitor phosphonoacetic acid (PAA) and total
179 protein harvested at given timepoints. Levels of CTD serine 7 phosphorylation (pS7) relative
180 to total RPB1 were quantified by Western blotting. (B) Means of at least three replicates
181 relative to the corresponding mock-infected sample plotted with standard deviations. (C) HFF
182 cells infected with HSV-1 KOS treated with PAA or KOS-derived mutants lacking the
183 combinations of immediate-early genes indicated in the table in the bottom right. White bars
184 indicate removal of irrelevant samples. Total protein was harvested at 8h p.i. and pS2/7 levels

185 determined by Western blot. (D) Quantification of phospho-serine levels normalized to total
186 RPB1. Means of three replicates normalized to mock-infected samples with PAA with
187 standard error are plotted, values from KOS are from PAA-treated samples. Statistically
188 significant differences to mock are indicated as * $p < 0.05$, ** $p < 0.01$.

189

190 Of the five viral IE genes, four (ICP0, ICP4, ICP22, and ICP27) show nuclear localization
191 and viral mutants lacking each of these genes were tested for their impacts on pS7. Contrary
192 to pS2, which accumulated to higher levels without ICP22 compared to the wild-type strain,
193 no individual viral IE gene seemed sufficient to account for the loss of pS7 (S2B Fig). The
194 addition of PAA with these mutants prevented some of the pS7 loss, indicating that viral late
195 genes and/or DNA replication, though not required, can facilitate CTD remodeling as
196 previously described (12,13,34). Importantly, no loss of pS7 was observed upon infection with
197 a mutant virus whose genome is not trafficked to the nucleus due to the removal of the
198 nuclear localization signal in the UL36 protein (dNLS, Fig 2C,D). Therefore, viral tegument
199 proteins delivered by the incoming virus particles are not sufficient to induce pS7 loss, as
200 indicated by the retention of pS7 when using cycloheximide alone (Fig. S2A).

201 As our data suggested the involvement of more than one viral gene product, a panel
202 of viruses lacking the major viral transcription factor ICP4 and combinations of the other IE
203 genes were tested. It is important to note that viral gene expression by these viruses is
204 restricted to the remaining four immediate early genes (ICP0, ICP22, ICP27 and ICP47.5). The
205 strongest reduction (~50%) in pS7 was observed in viruses expressing both ICP22 and ICP27
206 (KOS and d100, Fig 2C,D). Viruses lacking either ICP22 or ICP27 had an intermediate (~25%)
207 loss of pS7, while a virus lacking both proteins (d106) had no significant reduction. The
208 contribution of ICP22 to the loss of both pS2 and pS7 can be easily attributed to inhibition of

209 CDK9, while ICP27's impact on pS7 is less readily apparent. ICP27 is known to co-precipitate
210 with RPB1 (35,36) and other transcription factors such as SPT5; the latter interaction
211 facilitated by CDK9 activity (37). ICP27 has also been previously reported to reduce Ser2
212 phosphorylation in HeLa and RSF (36,38) –but not Vero (13)– cells. However, as the other
213 immediate-early mRNAs exhibit less cytoplasmic accumulation without ICP27 (39), an effect
214 on ICP22 expression cannot be ruled out for the impact on pS2. These data indicate that while
215 loss of ICP27 did not alter ICP22-mediated effects on serine 2 phosphorylation in infected
216 primary human fibroblasts, ICP22 and ICP27 work in a complementary manner to deplete
217 serine 7 phosphorylation that does not require viral late gene expression.

218

219 **HSV-1 utilizes multiple proteasome-dependent pathways to regulate**

220 **RPB1**

221 Early studies have shown that total transcriptional activity of all RNA polymerases in
222 HSV-infected cells rapidly shuts down after the peak of viral gene expression around 8h p.i.
223 (40–42), associated with Pol II holoenzyme remodeling (43) and degradation of RPB1 itself at
224 later timepoints (33). In addition to viral replication compartments, RPB1 localizes to virus-
225 induced chaperone (VICE) domains (36,38) which have been proposed to serve as sites of
226 quality control for protein folding and/or complex assembly as they contain numerous
227 chaperones and proteasome components (44,45). Protease activity and different types of
228 mono- and polyubiquitination have been detected in VICE domains, though it is not clear if all
229 proteins trafficked to these compartments are fated for degradation or if these can serve as
230 assembly sites for complicated higher-order protein structures (46).

231 While the exact roles of VICE domains in regulating transcription are unknown,
232 proteasome inhibitors which block VICE domain formation (36,38) were previously found to
233 prevent the loss of pS2 (36), and we observed this for pS7 as well (Fig 3A). Efficacy of the
234 proteasome inhibitors could be visualized by increased p53 levels and laddering indicating
235 polyubiquitination, and for RPB1 specifically accumulation of a high molecular weight (MW)
236 band likely corresponding to ubiquitinated RPB1 (38) and lower MW bands indicative of
237 degradation products could be observed in both infected and uninfected cells (S3A Fig).
238 Interestingly, the migratory shift of RPB1 from Ilo to Ili during gel electrophoresis could still
239 be observed in infected cells even though treated samples had relatively equal levels of pS2
240 and pS7 as uninfected controls (S3B Fig). We are unable to measure the levels of ICP22
241 expression under these settings due to the lack of a commercial antibody, but previous work
242 demonstrated that ICP22 expression is not altered by proteasome inhibition (47).

243

244 **Fig 3. Effects of proteasome inhibitors and RPB1 polyubiquitination mutants on HSV-1-**
245 **induced RPB1 remodeling.** (A) Human foreskin fibroblasts were infected with HSV-1 17syn+
246 and treated with indicated proteasome inhibitors for 8h before collection of total protein and
247 quantification of CTD Ser2 and Ser7 phosphorylation by Western blotting. Plotted are means
248 of two replicates with standard deviations. (B-D) 293T parental wild-type (WT) and clonally
249 derived RPB1 K1268R mutant cell lines were infected with HSV1(17+)-LoxCheVP26 and total
250 RPB1 or phosphorylated CTD serine residues quantified by Western blotting. (B) Relative
251 levels of CTD serine phosphorylation at 8h p.i.; plotted are three individual replicates with
252 longest lines indicating means and shortest standard error ranges. (C) Representative
253 Western blot of RPB1 levels in uninfected (Un.) 293T WT and RPB1 K1268R or cells infected

254 for 8 and 24h. (D) Relative RPB1 levels normalized to vinculin in infected 293T WT and RPB1
255 K1268R cells; plotted are means of at least three replicates with standard error.

256

257 Rice and colleagues have suggested that ICP22-mediated inhibition of pS2 is
258 mechanistically distinct from the degradation of hyperphosphorylated RPB1 (13). To this
259 point, we observed no significant loss of total RPB1 levels by 8h p.i. or immediately following
260 heat, osmotic, or oxidative stress using five different RPB1 antibodies (S4 Fig), indicating CTD
261 remodeling as the major effector or degradation of a very small percentage of RPB1 molecules
262 (as detectable by Western blot) which contain the vast majority of Ser2/7 –but not Ser5–
263 phosphorylation in the cell.

264 The most well-studied RPB1 degradation pathway occurs during transcription-coupled
265 repair where elongating Pol II stalls at sites of DNA damage and signals to repair machinery
266 via polyubiquitination of RPB1, leading to release of RPB1 from DNA and subsequent
267 degradation. Recent work demonstrated that this polyubiquitination occurs on a single lysine,
268 K1268; and while other sites of monoubiquitination exist, mutation of this single lysine to
269 arginine completely prevented degradation of RPB1 after UV irradiation (48). Two
270 monoclonal cell lines bearing the RPB1 K1268R mutation exhibited an equal loss of serine 2
271 and 7 phosphorylation during HSV-1 infection as the parental wild-type (WT) cell line by 8 h
272 p.i. (Fig 3B, S5A). As in primary fibroblasts, no major loss of RPB1 was observed by 8h p.i. in
273 any of the cell lines. By 24h p.i. however, RPB1 in WT cells was hardly detectable; migrating
274 almost exclusively as a lower MW smear while RPB1 K1268R mutant cells exhibited a ~50%
275 retention in total RPB1 protein (Fig 3C,D). Visualization of mCherry fused to the viral late gene
276 VP26 indicated that viral gene expression at 8 and 24h was comparable across all cell lines
277 and that this effect was not due to global differences in viral gene expression (S5B Fig). This

278 demonstrates that the RPB1 ubiquitination pathway active during DNA damage is not
279 involved in CTD remodeling during the bulk of viral gene expression, but may degrade Pol II
280 at later times during virion assembly and genome packaging. It is possible that the 50%
281 reduction of RPB1 in the K1268R cells may not be due to degradation, but standard protein
282 turnover coupled with the virus-induced shutoff of host mRNA translation as RPB1 is reported
283 to have a half-life of 6h in mammalian cell lines (49). Virus production in these cells was
284 measured to determine if RPB1 degradation facilitates productive infection and virus release,
285 however the two clones bearing the K1268R mutation gave differential phenotypes as the
286 mutant clone D12 produced viral progeny equal to WT cells while the E2 clone was
287 consistently ~5-fold lower than the other two cell lines (S5C Fig). Overall, these data indicate
288 that while proteasome-dependent pathways are active in CTD remodeling during lytic HSV-1
289 infection, they are separate from transcription-coupled repair and precede the bulk
290 degradation of RPB1.

291

292 **Herpesviral DNA recruits, but does not require, all CTD modifications**

293 During infection, Pol II is strongly enriched in viral replication compartments (9): large
294 compartments predominately assembled by viral DNA and the viral transcription factor ICP4
295 which recruit numerous factors for transcription, DNA replication, and virion assembly while
296 excluding host proteins such as histones and gene silencing factors (50). We sought to
297 determine which CTD modifications localized to viral DNA by immunofluorescence. Even
298 though HSV-1 infection reduced global pS2 and pS7 levels, these modifications were still
299 strongly enriched in ICP4 foci, as were all other CTD modifications tested (Fig 4); indicating
300 that no major CTD mark is excluded from the viral genome.

301

302 **Fig 4. Co-localization of RPB1 CTD modifications with viral replication compartments.**

303 Human foreskin fibroblasts were infected with HSV-1 strain 17syn+ for 8h before fixation.

304 Antibody staining was performed for viral protein ICP4, RPB1, and its respective CTD

305 modifications. p=phosphorylation, me=methylation.

306

307 Previous studies have shown that chemical inhibition of CDK9 reduces herpesviral

308 gene expression (51,52), indicating that HSV-1 still requires some degree of phosphorylation

309 on the CTD and/or other transcription factors. We decided to investigate the requirements of

310 viral genes for CTD serines 2 and 7 using an amanitin-based RPB1 replacement assay. HEK-

311 293T cells were co-transfected with a plasmid expressing the blue fluorescent protein Azurite

312 as a visual control for transfection efficiency and vectors expressing α -amanitin-resistant, HA-

313 tagged RPB1 constructs (53,54) containing either a wild-type (WT) CTD or mutant CTDs. The

314 mutations are non-phospho-accepting alanine substitutions in place of serines 2 or 7 (S2A and

315 S7A, respectively) or the phospho-serine mimic glutamic acid at serine 7 (S7E). After 24h, α -

316 amanitin was added to degrade endogenous RPB1 for an additional 24h, followed by infection

317 with fluorescent HSV-1 expressing eYFP-ICP0 as an immediate-early gene marker and gC-

318 mCherry as a late gene marker (55). As shown in Fig 5, detectable levels of IE and late genes

319 could be visualized in cells with replaced WT CTD at 24h p.i., albeit at substantially lower levels

320 than amanitin-untreated cells, but not with empty pcDNA3 vector control. As expected, both

321 early and late viral gene expression was reduced with CTD S2A mutants. In contrast, S7A

322 mutations expressed both classes viral genes equally well as the WT CTD. Interestingly, the

323 phospho-mimic S7E mutations completely ablated viral gene expression, moreso than S2A,

324 though this is likely due to reduced recruitment and/or 3'-end processing (54) as even Azurite
325 expression was reduced. Western blotting for the plasmid-expressed, HA-tagged RPB1
326 verified that expression of the exogenous RPB1 mutants were comparable across conditions
327 (S6 Fig). These data demonstrate that while viral DNA localizes all major CTD modifications,
328 not all are required for viral late gene expression. In the case of CTD serine 7, the amino acid
329 itself appears completely dispensable during lytic infection.

330

331 **Fig 5. CTD serine 2, but not serine 7, is required for efficient viral gene expression.** HEK-
332 293T cells were co-transfected with a construct expressing Azurite blue fluorescent protein
333 as a transfection marker and plasmids expressing amanitin-resistant RPB1 with wild-type
334 (WT) or indicated mutant CTDs, or the control vector pcDNA3 lacking any polymerase. The
335 next day, α -amanitin was added to degrade endogenous RPB1 for 24h followed by infection
336 with an eYFP-ICP0-/gC-mCherry-expressing HSV-1. Live-cell imaging was performed at 24h p.i.
337 All images were acquired with the same settings, with infection of untransfected, amanitin-
338 untreated cells included as a reference for the relative level of viral gene expression. PC:
339 phase contrast, S2A: serine 2 to alanine, S7A: serine 7 to alanine, S7E: serine 7 to glutamate.
340 Scale bars indicate 100 μ m.

341

342 **Discussion**

343 Post-translational modification, particularly phosphorylation, of the RPB1 CTD is at the
344 core of numerous transcriptional responses. Release of CDK9 from the 7SK snRNP and
345 resulting transcription P-TEFb-dependent genes greatly impacts mammalian cell survival
346 during genotoxic stress (56) and interferon responses during viral infection (57). As

347 phosphorylation of multiple CTD residues (namely Tyr1, Ser2, and Thr4) are involved in
348 termination of mammalian protein-coding genes, we reasoned that there could be a core
349 dysregulation of the CTD code in response to stress. However, we observed no major changes
350 in the CTD shared across all conditions tested. Both HSV-1 infection and heat stress induced
351 the intermediate-migrating Ili form of RPB1, while only HSV-1 showed a consistent loss of pS2
352 and pS7 with all antibodies tested. To avoid antibody bias, future work should implement
353 mass spectrometry-based assays (2,58) to quantify the phosphorylation states of the Ili forms
354 of RPB1 in heat stress and HSV-1 infection. Though different challenges to cellular
355 homeostasis can have similar global impacts on gene expression, particularly in regards to
356 inhibiting polyadenylation, our data demonstrate that this is not due to a common, global
357 disruption of the RPB1 CTD.

358 Western blotting of different viral mutants implicates *de novo* expression of both
359 ICP22 and ICP27 in the loss of pS7. While ICP22's known ability to regulate CDK9 can account
360 for this protein's contribution, ICP27 may work by other means. Beyond simply supporting
361 expression of other viral genes, ICP27 binds directly to RPB1 and could disrupt downstream
362 interactions and phosphorylation. Both ICP22 and ICP27 have been implicated in VICE domain
363 formation, and it is possible that RPB1 may interact with proteins in these domains that limit
364 its ability to be phosphorylated. Though VICE domains contain numerous components
365 involved in protein misfolding and degradation, we favor the view that they facilitate RPB1
366 remodeling and trafficking over proteolysis as we do not observe a major decrease in RPB1
367 levels until well after the decrease in pS2/7.

368 Our data supports previous observations that ongoing viral transcription is required
369 for CTD remodeling, as even relatively weak expression of immediate early genes can trigger
370 RPB1 degradation in cycloheximide/actinomycin D reversal assays. This particular

371 degradation pathway is likely separate from the one during DNA damage as it occurs when
372 transcription is chemically inhibited. We observed that degradation of RPB1 mediated by
373 polyubiquitination of K1268 is not involved in the loss of pS2/7, but stabilizes RPB1 24h p.i.
374 This suggests that there are multiple degradation pathways triggered by HSV-1 at different
375 stages of infection and reside in a balance with ongoing viral transcription or trafficking
376 between VICE domains and replication compartments (RCs). Degrading Pol II on viral DNA
377 may preserve genomes in settings of abortive infection by halting the production of viral
378 antigens or innate immune triggers like double-stranded RNA, or help maintain latency with
379 leaky transcription. It will be of interest to experimentally determine ubiquitination sites at
380 early and late timepoints of HSV-1 infection by mass spectrometry to better understand how
381 the proteasomal machinery is involved with viral transcription cycles and shuttling of RPB1
382 between the various nuclear compartments.

383 The interaction of ICP22 and CDK9 has been proposed to benefit HSV-1 by causing
384 reduced transcriptional elongation rates of cellular mRNA as a means of countering host
385 responses (11), and even to regulate viral genes themselves (59). However, chemical
386 inhibition of CDK9 also reduces viral gene expression and our data with S2A mutants
387 recapitulates this phenotype, indicating a beneficial role for at least intermediate pS2 levels
388 in regards to viral genes. Contrary to this, polymerases with S7A mutations expressed viral
389 proteins comparable to the WT CTD, demonstrating that the entire CTD code is not required
390 for herpesviral gene expression despite the fact that all modifications we could test are
391 localized to viral replication compartments. The presence of pS7 on the viral genome may
392 therefore be a consequence of recruiting kinases for their other, necessary phosphorylation
393 events or serve to sequester transcription factors away from host chromatin. We also cannot
394 rule out the possibility that Ser7 regulation may be more impactful during reactivation from

395 latency over lytic infection or during inflammatory responses. Indeed, inhibition of another
396 Ser7 kinase, CDK7, has been shown to reduce cytokine release and inflammation (60,61), but
397 more work is required to determine contributions from Ser7 vs. other CDK7 targets, especially
398 CTD Ser5.

399 Currently, the best described role of pS7 is recruitment of the Integrator complex to
400 snRNA genes (62) for 3'-end formation of Pol II-derived snRNA (63). Disrupting snRNA
401 formation by itself is unlikely to influence lytic infection as the rapid redirection of Pol II
402 activity to viral genomes and transcriptional shutdown within the span of 8-12h would not be
403 expected to alter the abundant pool of mature splicing factors, and most viral genes are
404 unspliced late in infection when these termination defects are the greatest. Integrator also
405 has direct roles in regulating protein-coding genes, and knockdown of its catalytic subunit
406 recapitulates termination defects on a subset of host mRNAs disrupted during osmotic stress
407 (64), though our previous work implicates ICP27-CPSF interactions as the primary
408 determinant during HSV-1 infection (10). Work is ongoing to analyze the role of integrator in
409 HSV-1 infection. The reduction of pS7 could also result in more subtle, global consequences
410 on host gene expression as pS7 has been proposed to suppress cryptic transcription (65) as
411 well as stimulate Ser2 phosphorylation by CDK9 and CDK12 (66,67). Our future efforts will
412 involve mapping the genomic locations of pS/7 during infection by ChIP/mNET-seq to better
413 understand the impacts of herpesviral-induced CTD remodeling.

414

415 **Materials and Methods**

416 **Cell lines and viruses**

417 Human foreskin fibroblasts were purchased from ECACC and ATCC. BHK-21 cells were
418 purchased from ATCC. 293T RPB1 K1268R clones D12 and E2 as well as the corresponding
419 parental cell line (48) were gifts from Jesper Svejstrup, Francis Crick Institute. Vero cells were
420 provided by Beate Sodeik, Hannover Medical School, and Vero derivatives E5 (68) and F06
421 (69) were gifts from Neal A. DeLuca, University of Pittsburg and Vero 2-2 (70) from Rozanne
422 M. Sandri-Goldin, UC Irvine. RSC and RSC-HAUL36 (71) were provided by Peter O'Hare,
423 Imperial College London. All cells were cultured in Dulbecco's Modified Eagle Medium
424 (DMEM), high glucose, pyruvate (ThermoFisher #41966052) supplemented with 1x MEM
425 Non-Essential Amino Acids (ThermoFisher #11140050), 1mM additional sodium pyruvate
426 (ThermoFisher #11360070), 10% (v/v) Fetal Bovine Serum (FBS, Biochrom #S 0115), 200
427 IU/mL penicillin and 200 µg/mL streptomycin. All cells were incubated at 37°C in a 5% (v/v)
428 CO₂-enriched incubator.

429 KOS strain ICP4 mutant n12 (68) and KOS 1.1 ICP27 mutant 27-lacZ (70) were
430 propagated on E5 cells and Vero2-2 cells, respectively. KOS BAC-derived VP1-2ΔNLS (72) was
431 cultured as previously described in RSC cells. Wild type strains 17syn+ and F, along with BAC-
432 derived strains KOS and HSV1(17+)-LoxCheVP26 (73) were propagated on BHK-21 cells as well
433 strain 17 ICP0 mutant dl1403 (74), strain F ICP22 mutant Δ325 (75), as well as the KOS eYFP-
434 ICP0/gC-mCherry BAC-derived virus (55), which was generously provided by Colin Crump,
435 University of Cambridge. KOS mutants d100, d103, d104, d106, and d107 (76) were grown
436 and titered on F06 cells.

437 293T cell lines were seeded onto poly-lysine-coated dishes for infection experiments.
438 All infections, except those for virus growth curves, were performed with an MOI of 10 by
439 diluting virus in serum-free DMEM and adsorbing for 1h at 37°C to cells plated the previous
440 day. Virus production assays were similarly infected but with an MOI of 0.01. Afterwards,

441 inoculum was replaced with culturing medium or medium containing concentrations of
442 compounds described below.

443

444 **Stress and drug treatments**

445 Heat stress was initiated by adding pre-warmed 44°C medium to cells and culturing
446 for 2h at 44°C. Salt stress and oxidative stress were initiated by adding KCl or sodium arsenite
447 to concentrations of 80mM and 0.5mM, respectively, for 1h. Mock cells were harvested at
448 timepoint 0 and infected cells at 8h p.i.

449 Phosphonoacetic acid (PAA, Sigma #284270) was used at a concentration of 300
450 µg/mL when indicated. Bortezomib (Selleckchem #S1013) was used at a concentration of
451 5µM, epoxomicin (Cayman Chemical #10007806) and MG132 (Sigma #M7449) both at 10µM,
452 with equal volumes of DMSO vehicle used as control. Actinomycin D was used at 5 µg/mL and
453 cycloheximide at 100 µg/mL for the times indicated in the text. Uninfected cells for drug
454 treatments were harvested at the final timepoints as infected samples.

455

456 **Western blotting**

457 A full description of antibodies is found in S1 Table. Total protein samples were
458 harvested by lysing cells directly in Laemmli buffer at given timepoints. Samples were
459 resolved on 6% tris-glycine SDS PAGE gels with a 4% stacking gel, both 37.5:1
460 acrylamide:bisacrylamide, and transferred overnight in tris-glycine buffer containing 20%
461 (v/v) methanol to 0.45µm nitrocellulose membranes. Membranes were rinsed with deionized
462 water and blocked in tris-buffered saline with 0.1% (v/v) Tween 20 (TBST) with 5% (w/v) milk
463 for 1h before overnight binding with primary antibodies diluted in blocking buffer. Samples

464 were washed in TBST, blocked for one additional hour, and secondary antibodies allowed to
465 bind for one hour before final TBST washes and visualization on a LI-COR Odyssey Fc imaging
466 system. Deviations from this procedure are indicated in the relevant figure legends.

467 Band densitometry was performed using Image Studio Light (LI-COR). Total RPB1
468 levels for each sample were normalized to vinculin signal on the same membrane. Signals for
469 each CTD modification were normalized to total RPB1 levels on the same membrane. The
470 relative ratios are compared to mock samples on the same membrane, which was set to
471 100%. Statistical significance was determined using two-way ANOVA in GraphPad Prism.

472

473 **Immunofluorescence**

474 3×10^4 HFF cells were seeded onto 8 well glass chamber slides (Ibidi #80841). The
475 following day, cells were infected at an MOI of 10 and fixed 8h p.i. in 4% formaldehyde in PBS
476 for 15 minutes. After washing in PBS, cells were incubated in permeabilization buffer (10%
477 [v/v] FBS, 0.5% [v/v] Triton X-100, 250mM glycine, 1x PBS) for 10 minutes, then blocked for
478 1h in blocking buffer (10% [v/v] FBS, 250mM glycine, 1x PBS). Primary antibodies were
479 incubated overnight at 4°C in 10% (v/v) FBS and 1x TBS. The secondary antibodies were
480 incubated in 10% FBS in 1x TBS for 1h at room temperature with 1 µg/mL 4',6-diamidino-2-
481 phenylindole (DAPI). A full description of antibodies is found in S1 Table. Coverslips were
482 washed in water before mounting them in medium containing Mowiol 4-88 and 2.5% (w/v)
483 1,4-diazabicyclo[2.2.2]octane (DABCO). All steps before antibody binding were followed by
484 three 5-minute washes in PBS, while TBS was used after antibody binding. Samples were
485 imaged on a Zeiss LSM 780 where slices of 0.5µm were taken and intensities of each slice

486 summed in Fiji (77) to produce the 2D images provided. Live-cell imaging of fluorescent
487 viruses was performed on a Leica DMI8.

488

489 **RPB1 replacement assay**

490 5×10^4 HEK-293T cells were seeded in poly-lysine-coated 48-well plates. The next day,
491 cells were transfected with 15ng of pLV-Azurite (gift of Pantelis Tsoulfas, Addgene #36086)
492 and 250ng of vectors expressing HA-tagged, amanitin-resistant RPB1 constructs with the
493 mutant CTDs or pcDNA3 as a negative control via polyethylenimine (PEI). The WT and S2A
494 mutant are described in (53), the S7A and S7E mutants in (54). All RPB1 constructs were
495 generous gifts of Dirk Eick, LMU Munich. After 24h, media was exchanged for fresh growth
496 medium with 2.5 $\mu\text{g}/\text{mL}$ α -amanitin for an additional 24h. Cells were infected with eYFP-
497 ICP0/gC-mCherry HSV-1 at MOI 10 as described above in serum-free medium for 1h. This
498 inoculum was removed and amanitin-containing growth medium reapplied until imaging 24h
499 p.i.

500

501 **Acknowledgements**

502 We would like to thank Dirk Eick for the mutant RPB1 vectors and methyl-CTD K7 antibody,
503 Neal DeLuca and Roz Sandri-Goldin for providing HSV-1 deletion mutants and complementing
504 cell lines, as well as Colin Crump and Beate Sodeik for fluorescent BAC viruses. This work was
505 supported by the Deutsche Forschungsgemeinschaft (DFG grant DO1275/6-1) and the
506 European Union (ERC-2016-CoG 721016-HERPES) to L.D. A.W.W. was the recipient of a
507 generous grant from the Alexander von Humboldt Foundation and the German Federal
508 Foreign Office.

509

510 **Contributions**

511 A.W.W. and L.D. conceived and designed the experiments and wrote the paper. A.W.W.

512 performed the experiments with the help of O.D.D., A.G., J.M.R., A.L.M., and S.S.S.

513

514 **References**

515 1. Fields BN, Knipe DM (David M, Howley PM. Fields virology. Wolters Kluwer

516 Health/Lippincott Williams & Wilkins; 2013. 82 p.

517 2. Schüller R, Forné I, Straub T, Schreieck A, Texier Y, Shah N, et al. Heptad-Specific

518 Phosphorylation of RNA Polymerase II CTD. Mol Cell [Internet]. 2016 Jan 21 [cited

519 2017 Aug 14];61(2):305–14. Available from:

520 <http://www.ncbi.nlm.nih.gov/pubmed/26799765>

521 3. Zaborowska J, Egloff S, Murphy S. The pol II CTD: New twists in the tail. Vol. 23,

522 Nature Structural and Molecular Biology. Nature Publishing Group; 2016. p. 771–7.

523 4. Abrisch RG, Eidem TM, Yakovchuk P, Kugel JF, Goodrich JA. Infection by Herpes

524 Simplex Virus 1 Causes Near-Complete Loss of RNA Polymerase II Occupancy on the

525 Host Cell Genome. Sandri-Goldin RM, editor. J Virol [Internet]. 2016 Mar 1 [cited 2018

526 Sep 4];90(5):2503–13. Available from:

527 <http://www.ncbi.nlm.nih.gov/pubmed/26676778>

528 5. Dremel SE, Deluca NA. Herpes simplex viral nucleoprotein creates a competitive

529 transcriptional environment facilitating robust viral transcription and host shut off.

530 Elife. 2019 Oct 1;8.

531 6. Birkenheuer CH, Danko CG, Baines JD. Herpes Simplex Virus 1 Dramatically Alters

- 532 Loading and Positioning of RNA Polymerase II on Host Genes Early in Infection.
- 533 Sandri-Goldin RM, editor. *J Virol* [Internet]. 2018 Feb 7 [cited 2018 Sep
- 534 4];92(8):e02184-17. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29437966>
- 535 7. Birkenheuer CH, Baines JD. RNA polymerase II Promoter Proximal Pausing and
- 536 Release to Elongation are Key Steps Regulating Herpes Simplex Virus 1 Transcription.
- 537 *J Virol* [Internet]. 2019 Dec 11 [cited 2020 Jan 9]; Available from:
- 538 <http://www.ncbi.nlm.nih.gov/pubmed/31826988>
- 539 8. Rutkowski AJ, Erhard F, L'Hernault A, Bonfert T, Schilhabel M, Crump C, et al.
- 540 Widespread disruption of host transcription termination in HSV-1 infection. *Nat*
- 541 *Commun* [Internet]. 2015 May 20 [cited 2017 Aug 6];6:7126. Available from:
- 542 <http://www.ncbi.nlm.nih.gov/pubmed/25989971>
- 543 9. McSwiggen DT, Hansen AS, Teves SS, Marie-Nelly H, Hao Y, Heckert AB, et al.
- 544 Evidence for DNA-mediated nuclear compartmentalization distinct from phase
- 545 separation. *Elife*. 2019 Apr 1;8.
- 546 10. Wang X, Hennig T, Whisnant AW, Erhard F, Prusty BK, Friedel CC, et al. Herpes
- 547 simplex virus blocks host transcription termination via the bimodal activities of ICP27.
- 548 *Nat Commun* [Internet]. 2020 Dec 15 [cited 2020 Jan 16];11(1):293. Available from:
- 549 <http://www.nature.com/articles/s41467-019-14109-x>
- 550 11. Zaborowska J, Baumli S, Laitem C, O'Reilly D, Thomas PH, O'Hare P, et al. Herpes
- 551 Simplex Virus 1 (HSV-1) ICP22 Protein Directly Interacts with Cyclin-Dependent Kinase
- 552 (CDK)9 to Inhibit RNA Polymerase II Transcription Elongation. Yenugu S, editor. *PLoS*
- 553 *One* [Internet]. 2014 Sep 18 [cited 2020 Jan 13];9(9):e107654. Available from:
- 554 <https://dx.plos.org/10.1371/journal.pone.0107654>
- 555 12. Durand LO, Advani SJ, Poon APW, Roizman B. The carboxyl-terminal domain of RNA

- 556 polymerase II is phosphorylated by a complex containing cdk9 and infected-cell
557 protein 22 of herpes simplex virus 1. *J Virol* [Internet]. 2005 Jun [cited 2018 Nov
558 30];79(11):6757–62. Available from:
559 <http://www.ncbi.nlm.nih.gov/pubmed/15890914>
- 560 13. Fraser KA, Rice SA. Herpes Simplex Virus Immediate-Early Protein ICP22 Triggers Loss
561 of Serine 2-Phosphorylated RNA Polymerase II. *J Virol* [Internet]. 2007 [cited 2019
562 May 7];81(10):5091–101. Available from:
563 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1900222/pdf/0184-07.pdf>
- 564 14. Wiesel Y, Sabath N, Shalgi R. DoGFinder: A software for the discovery and
565 quantification of readthrough transcripts from RNA-seq. *BMC Genomics*. 2018 Aug
566 8;19(1):1–7.
- 567 15. Giannakakis A, Zhang J, Jenjaroenpun P, Nama S, Zainolabidin N, Aau MY, et al.
568 Contrasting expression patterns of coding and noncoding parts of the human genome
569 upon oxidative stress. *Sci Rep*. 2015 May 29;5.
- 570 16. Vilborg A, Passarelli MC, Yario TA, Tycowski KT, Steitz JA. Widespread Inducible
571 Transcription Downstream of Human Genes. *Mol Cell*. 2015 Aug 6;59(3):449–61.
- 572 17. Vilborg A, Sabath N, Wiesel Y, Nathans J, Levy-Adam F, Yario TA, et al. Comparative
573 analysis reveals genomic features of stress-induced transcriptional readthrough. *Proc*
574 *Natl Acad Sci U S A*. 2017 Oct 3;114(40):E8362–71.
- 575 18. Cardiello JF, Goodrich JA, Kugel JF. Heat Shock Causes a Reversible Increase in RNA
576 Polymerase II Occupancy Downstream of mRNA Genes, Consistent with a Global Loss
577 in Transcriptional Termination. *Mol Cell Biol* [Internet]. 2018 Jul 2 [cited 2018 Sep
578 4];38(18). Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29967245>
- 579 19. Grosso AR, Leite AP, Carvalho S, Matos MR, Martins FB, Vítor AC, et al. Pervasive

- 580 transcription read-through promotes aberrant expression of oncogenes and RNA
581 chimeras in renal carcinoma. *Elife*. 2015 Nov 17;4(NOVEMBER2015).
- 582 20. Hennig T, Michalski M, Rutkowski AJ, Djakovic L, Whisnant AW, Friedl M-S, et al. HSV-
583 1-induced disruption of transcription termination resembles a cellular stress response
584 but selectively increases chromatin accessibility downstream of genes. *PLoS Pathog*.
585 2018;14(3).
- 586 21. Harlen KM, Trotta KL, Smith EE, Mosaheb MM, Fuchs SM, Churchman LS.
587 Comprehensive RNA Polymerase II Interactomes Reveal Distinct and Varied Roles for
588 Each Phospho-CTD Residue. *Cell Rep*. 2016 Jun 7;15(10):2147–58.
- 589 22. Hsin JP, Sheth A, Manley JL. RNAP II CTD phosphorylated on threonine-4 is required
590 for histone mRNA 3' end processing. *Science (80-)*. 2011 Nov 4;334(6056):683–6.
- 591 23. Hintermair C, Heidemann M, Koch F, Descostes N, Gut M, Gut I, et al. Threonine-4 of
592 mammalian RNA polymerase II CTD is targeted by Polo-like kinase 3 and required for
593 transcriptional elongation. *EMBO J*. 2012 Jun 13;31(12):2784–97.
- 594 24. Yurko N, Liu X, Yamazaki T, Hoque M, Tian B, Manley Correspondence JL. MPK1/SLT2
595 Links Multiple Stress Responses with Gene Expression in Budding Yeast by
596 Phosphorylating Tyr1 of the RNAP II CTD In Brief. *Mol Cell [Internet]*. 2017 [cited 2020
597 Jan 13];68:913-925.e3. Available from: <https://doi.org/10.1016/j.molcel.2017.11.020>
- 598 25. Nojima T, Gomes T, Grosso ARF, Kimura H, Dye MJ, Dhir S, et al. Mammalian NET-seq
599 reveals genome-wide nascent transcription coupled to RNA processing. *Cell*.
600 2015;161(3).
- 601 26. Voss K, Forné I, Descostes N, Hintermair C, Schüller R, Maqbool MA, et al. Site-specific
602 methylation and acetylation of lysine residues in the C-terminal domain (CTD) of RNA
603 polymerase II. *Transcription*. 2015 Oct 20;6(5):91–101.

- 604 27. Dubois M-F, Bellier S, Seo S-J, Bensaude O. Phosphorylation of the RNA Polymerase II
605 Largest Subunit During Heat Shock and Inhibition of Transcription in Hela Cells. *J Cell*
606 *Physiol* [Internet]. 1994 Mar [cited 2019 Aug 8];158(3):417–26. Available from:
607 <http://doi.wiley.com/10.1002/jcp.1041580305>
- 608 28. Venetianer A, Dubois M-F, Nguyen VT, Bellier S, Seo S-J, Bensaude O. Phosphorylation
609 State of the RNA Polymerase II C-Terminal Domain (CTD) in Heat-Shocked Cells.
610 Possible Involvement of the Stress-Activated Mitogen-Activated Protein (MAP)
611 Kinases. *Eur J Biochem* [Internet]. 1995 Oct 1 [cited 2019 Aug 8];233(1):83–92.
612 Available from: http://doi.wiley.com/10.1111/j.1432-1033.1995.083_1.x
- 613 29. Dubois M-F, Marshall NF, Nguyen VT, Dahmus GK, Bonnet F, Dahmus ME, et al. Heat
614 shock of HeLa cells inactivates a nuclear protein phosphatase specific for
615 dephosphorylation of the C-terminal domain of RNA polymerase II [Internet]. Vol. 27,
616 *Nucleic Acids Research*. 1999 [cited 2020 Jan 13]. Available from:
617 <https://academic.oup.com/nar/article-abstract/27/5/1338/2902213>
- 618 30. Yakovchuk P, Goodrich JA, Kugel JF. B2 RNA represses TFIIH phosphorylation of RNA
619 polymerase II. *Transcription*. 2011;2(1):45–9.
- 620 31. Schrieck A, Easter AD, Etzold S, Wiederhold K, Lidschreiber M, Cramer P, et al. RNA
621 polymerase II termination involves C-terminal-domain tyrosine dephosphorylation by
622 CPF subunit Glc7. *Nat Struct Mol Biol*. 2014 Feb 12;21(2):175–9.
- 623 32. Shah N, Maqbool MA, Yahia Y, El Aabidine AZ, Esnault C, Forné I, et al. Tyrosine-1 of
624 RNA Polymerase II CTD Controls Global Termination of Gene Transcription in
625 Mammals. *Mol Cell*. 2018 Jan 4;69(1):48-61.e6.
- 626 33. Rice SA, Long MC, Lam V, Spencer CA. RNA polymerase II is aberrantly
627 phosphorylated and localized to viral replication compartments following herpes

- 628 simplex virus infection. *J Virol* [Internet]. 1994 Feb [cited 2020 Jan 13];68(2):988–
629 1001. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8289400>
- 630 34. Long MC, Leong V, Schaffer PA, Spencer CA, Rice SA. ICP22 and the UL13 protein
631 kinase are both required for herpes simplex virus-induced modification of the large
632 subunit of RNA polymerase II. *J Virol* [Internet]. 1999 Jul [cited 2017 Aug
633 14];73(7):5593–604. Available from:
634 <http://www.ncbi.nlm.nih.gov/pubmed/10364308>
- 635 35. Zhou C, Knipe DM. Association of Herpes Simplex Virus Type 1 ICP8 and ICP27
636 Proteins with Cellular RNA Polymerase II Holoenzyme. *J Virol* [Internet]. 2002 Jun 15
637 [cited 2017 Aug 4];76(12):5893–904. Available from:
638 <http://jvi.asm.org/cgi/doi/10.1128/JVI.76.12.5893-5904.2002>
- 639 36. Dai-Ju JQ, Li L, Johnson LA, Sandri-Goldin RM. ICP27 interacts with the C-terminal
640 domain of RNA polymerase II and facilitates its recruitment to herpes simplex virus 1
641 transcription sites, where it undergoes proteasomal degradation during infection. *J*
642 *Virol* [Internet]. 2006 Apr [cited 2017 Aug 6];80(7):3567–81. Available from:
643 <http://www.ncbi.nlm.nih.gov/pubmed/16537625>
- 644 37. Zhao Z, Tang KW, Muylaert I, Samuelsson T, Elias P. CDK9 and SPT5 proteins are
645 specifically required for expression of herpes simplex virus 1 replication-dependent
646 late genes. *J Biol Chem*. 2017;292(37):15489–500.
- 647 38. Li L, Johnson LA, Dai-Ju JQ, Sandri-Goldin RM. Hsc70 Focus Formation at the Periphery
648 of HSV-1 Transcription Sites Requires ICP27. Jin D-Y, editor. *PLoS One* [Internet]. 2008
649 Jan 30 [cited 2020 Jan 9];3(1):e1491. Available from:
650 <http://dx.plos.org/10.1371/journal.pone.0001491>
- 651 39. Whisnant AW, Jürges CS, Hennig T, Wyler E, Prusty B, Rutkowski AJ, et al. Integrative

- 652 functional genomics decodes herpes simplex virus 1. *Nat Commun* [Internet]. 2020
653 Dec 27 [cited 2020 May 4];11(1):2038. Available from:
654 <http://www.nature.com/articles/s41467-020-15992-5>
- 655 40. Hay J, Köteles GJ, Keir HM, Subak Sharpe H. Herpes virus specified ribonucleic acids.
656 *Nature* [Internet]. 1966;210(5034):387–90. Available from:
657 <https://www.nature.com/nature/journal/v210/n5034/pdf/210387b0.pdf>
- 658 41. Flanagan JF. Virus-specific Ribonucleic Acid Synthesis in KB Cells Infected with Herpes
659 Simplex Virus Downloaded from [Internet]. Vol. 1, *JOURNAL OF VIROLOGY*. 1967
660 [cited 2020 Jan 13]. Available from: <http://jvi.asm.org/>
- 661 42. Spencer CA, Dahmus ME, Rice SA. Repression of host RNA polymerase II transcription
662 by herpes simplex virus type 1. *J Virol* [Internet]. 1997 Mar [cited 2017 Aug
663 6];71(3):2031–40. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9032335>
- 664 43. Jenkins HL, Spencer CA. RNA Polymerase II Holoenzyme Modifications Accompany
665 Transcription Reprogramming in Herpes Simplex Virus Type 1-Infected Cells. *J Virol*
666 [Internet]. 2001 Oct 15 [cited 2017 Aug 4];75(20):9872–84. Available from:
667 <http://jvi.asm.org/cgi/doi/10.1128/JVI.75.20.9872-9884.2001>
- 668 44. Burch AD, Weller SK. Nuclear Sequestration of Cellular Chaperone and Proteasomal
669 Machinery during Herpes Simplex Virus Type 1 Infection. *J Virol*. 2004 Jul
670 1;78(13):7175–85.
- 671 45. Adlakha M, Livingston CM, Bezsonova I, Weller SK. The HSV-1 immediate early
672 protein ICP22 is a functional mimic of a cellular J-protein. *J Virol* [Internet]. 2019 Nov
673 20 [cited 2020 Jan 16]; Available from:
674 <http://jvi.asm.org/lookup/doi/10.1128/JVI.01564-19>
- 675 46. Livingston CM, Ifrim MF, Cowan AE, Weller SK. Virus-Induced Chaperone-Enriched

- 676 (VICE) domains function as nuclear protein quality control centers during HSV-1
677 infection. *PLoS Pathog.* 2009;5(10).
- 678 47. Durand LO, Roizman B. Role of cdk9 in the optimization of expression of the genes
679 regulated by ICP22 of herpes simplex virus 1. *J Virol* [Internet]. 2008 Nov 1 [cited
680 2019 May 7];82(21):10591–9. Available from:
681 <http://www.ncbi.nlm.nih.gov/pubmed/18753202>
- 682 48. Tufegdžić Vidaković A, Mitter R, Kelly GP, Neumann M, Harreman M, Rodríguez-
683 Martínez M, et al. Regulation of the RNAPII Pool Is Integral to the DNA Damage
684 Response. *Cell.* 2020;
- 685 49. Akhrymuk I, Kulemzin S V., Frolova EI. Evasion of the Innate Immune Response: the
686 Old World Alphavirus nsP2 Protein Induces Rapid Degradation of Rpb1, a Catalytic
687 Subunit of RNA Polymerase II. *J Virol.* 2012 Jul 1;86(13):7180–91.
- 688 50. Kim ET, Dybas JM, Kulej K, Reyes ED, Price AM, Akhtar LN, et al. Comparative
689 proteomics identifies Schlafen 5 (SLFN5) as a herpes simplex virus restriction factor
690 that suppresses viral transcription. *Nat Microbiol.* 2021;
- 691 51. Ou M, Sandri-Goldin RM. Inhibition of cdk9 during Herpes Simplex Virus 1 Infection
692 Impedes Viral Transcription. Leib DA, editor. *PLoS One* [Internet]. 2013 Oct 18 [cited
693 2019 May 3];8(10):e79007. Available from:
694 <https://dx.plos.org/10.1371/journal.pone.0079007>
- 695 52. Alfonso-Dunn R, Arbuckle JH, Vogel JL, Kristie TM. Inhibition of the super elongation
696 complex suppresses herpes simplex virus immediate early gene expression, lytic
697 infection, and reactivation from latency. *MBio.* 2020 May 1;11(3):1–14.
- 698 53. Gu B, Eick D, Bensaude O. CTD serine-2 plays a critical role in splicing and termination
699 factor recruitment to RNA polymerase II in vivo. *Nucleic Acids Res.* 2013;

- 700 54. Egloff S, O'Reilly D, Chapman RD, Taylor A, Tanzhaus K, Pitts L, et al. Serine-7 of the
701 RNA polymerase II CTD is specifically required for snRNA gene expression. *Science*
702 (80-). 2007 Dec 14;318(5857):1777–9.
- 703 55. Scherer KM, Manton JD, Soh TK, Mascheroni L, Connor V, Crump CM, et al. A
704 fluorescent reporter system enables spatiotemporal analysis of host cell modification
705 during herpes simplex virus-1 replication. *J Biol Chem*. 2021;
- 706 56. Bugai A, Quaresma AJC, Friedel CC, Lenasi T, Düster R, Sibley CR, et al. P-TEFb
707 Activation by RBM7 Shapes a Pro-survival Transcriptional Response to Genotoxic
708 Stress. *Mol Cell*. 2019 Apr 18;74(2):254-267.e10.
- 709 57. Tian B, Zhao Y, Kalita M, Edeh CB, Paessler S, Casola A, et al. CDK9-Dependent
710 Transcriptional Elongation in the Innate Interferon-Stimulated Gene Response to
711 Respiratory Syncytial Virus Infection in Airway Epithelial Cells. *J Virol*. 2013 Jun
712 15;87(12):7075–92.
- 713 58. Suh H, Ficarro SB, Kang UB, Chun Y, Marto JA, Buratowski S. Direct Analysis of
714 Phosphorylation Sites on the Rpb1 C-Terminal Domain of RNA Polymerase II. *Mol Cell*.
715 2016 Jan 21;61(2):297–304.
- 716 59. Guo L, Wu W juan, Liu L ding, Wang L chun, Zhang Y, Wu L qiu, et al. Herpes Simplex
717 Virus 1 ICP22 Inhibits the Transcription of Viral Gene Promoters by Binding to and
718 Blocking the Recruitment of P-TEFb. *PLoS One* [Internet]. 2012 Sep 24 [cited 2021 Jun
719 22];7(9):31100127. Available from: <http://www.973.gov.cn/>
- 720 60. Hong H, Zeng Y, Jian W, Li L, Lin L, Mo Y, et al. CDK7 inhibition suppresses rheumatoid
721 arthritis inflammation via blockage of NF-κB activation and IL-1β/IL-6 secretion. *J Cell*
722 *Mol Med*. 2018;
- 723 61. Wei Y, Li C, Bian H, Qian W, Jin K, Xu T, et al. Targeting CDK7 suppresses super

- 724 enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine
725 release syndrome. *Mol Cancer*. 2021;
- 726 62. Egloff S, Zaborowska J, Laitem C, Kiss T, Murphy S. Ser7 phosphorylation of the CTD
727 recruits the RPAP2 ser5 phosphatase to snRNA genes. *Mol Cell*. 2012;
- 728 63. Egloff S, Szczepaniak SA, Dienstbier M, Taylor A, Knight S, Murphy S. The integrator
729 complex recognizes a new double mark on the RNA polymerase II carboxyl-terminal
730 domain. *J Biol Chem [Internet]*. 2010 Jul 2 [cited 2019 Aug 8];285(27):20564–9.
731 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20457598>
- 732 64. Rosa-Mercado NA, Zimmer JT, Apostolidi M, Rinehart J, Simon MD, Steitz JA.
733 Hyperosmotic stress alters the RNA polymerase II interactome and induces
734 readthrough transcription despite widespread transcriptional repression. *Mol Cell*.
735 2021;
- 736 65. Tietjen JR, Zhang DW, Rodríguez-Molina JB, White BE, Akhtar MS, Heidemann M, et
737 al. Chemical-genomic dissection of the CTD code. *Nat Struct Mol Biol*. 2010;
- 738 66. Czudnochowski N, Bösken CA, Geyer M. Serine-7 but not serine-5 phosphorylation
739 primes RNA polymerase II CTD for P-TEFb recognition. *Nat Commun*. 2012;
- 740 67. Bösken CA, Farnung L, Hintermair C, Schachter MM, Vogel-Bachmayr K, Blazek D, et
741 al. The structure and substrate specificity of human Cdk12/Cyclin K. *Nat Commun*.
742 2014;
- 743 68. DeLuca NA, Schaffer PA. Physical and functional domains of the herpes simplex virus
744 transcriptional regulatory protein ICP4. *J Virol [Internet]*. 1988 Mar [cited 2019 Dec
745 13];62(3):732–43. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2828668>
- 746 69. Samaniego LA, Wu N, Deluca NA. The Herpes Simplex Virus Immediate-Early Protein
747 ICP0 Affects Transcription from the Viral Genome and Infected-Cell Survival in the

- 748 Absence of ICP4 and ICP27. *J Virol* [Internet]. 1997 [cited 2018 May 25];71(6):4614–
749 25. Available from:
750 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC191683/pdf/714614.pdf>
- 751 70. Smith IL, Hardwicke MA, Sandri-Goldin RM. Evidence that the herpes simplex virus
752 immediate early protein ICP27 acts post-transcriptionally during infection to regulate
753 gene expression. *Virology* [Internet]. 1992 Jan [cited 2018 May 25];186(1):74–86.
754 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/1309283>
- 755 71. Roberts APE, Abaitua F, O’Hare P, McNab D, Rixon FJ, Pasdeloup D. Differing Roles of
756 Inner Tegument Proteins pUL36 and pUL37 during Entry of Herpes Simplex Virus Type
757 1. *J Virol*. 2009 Jan 1;83(1):105–16.
- 758 72. Abaitua F, Hollinshead M, Bolstad M, Crump CM, O’hare P. A Nuclear Localization
759 Signal in Herpesvirus Protein VP1-2 Is Essential for Infection via Capsid Routing to the
760 Nuclear Pore. 2012 [cited 2019 Dec 13]; Available from: <http://jvi.asm.org/>.
- 761 73. Sandbaumhüter M, Döhner K, Schipke J, Binz A, Pohlmann A, Sodeik B, et al. Cytosolic
762 herpes simplex virus capsids not only require binding inner tegument protein pUL36
763 but also pUL37 for active transport prior to secondary envelopment. *Cell Microbiol*
764 [Internet]. 2013 Feb [cited 2018 May 25];15(2):248–69. Available from:
765 <http://www.ncbi.nlm.nih.gov/pubmed/23186167>
- 766 74. Stow ND, Stow EC. Isolation and characterization of a herpes simplex virus type 1
767 mutant containing a deletion within the gene encoding the immediate early
768 polypeptide Vmw110. *J Gen Virol*. 1986;67(12):2571–85.
- 769 75. Post LE, Roizman B. A generalized technique for deletion of specific genes in large
770 genomes: a gene 22 of herpes simplex virus 1 is not essential for growth. *Cell*.
771 1981;25(1):227–32.

- 772 76. Samaniego LA, Neiderhiser L, Deluca NA. Persistence and Expression of the Herpes
773 Simplex Virus Genome in the Absence of Immediate-Early Proteins [Internet]. Vol. 72,
774 JOURNAL OF VIROLOGY. 1998 [cited 2019 Dec 13]. Available from: <http://jvi.asm.org/>
- 775 77. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: An
776 open-source platform for biological-image analysis. Vol. 9, Nature Methods. 2012. p.
777 676–82.
- 778

779 **Supporting Information**

780 **S1 Fig. Measurement of RPB1 CTD serine phosphorylation after exposure to stress using**
781 **different antibodies.** Human foreskin fibroblasts were subjected to mock treatment (lane 1),
782 heat stress (lane 2; 44°C, 2h), HSV-1 infection (lane 3; strain 17syn+, MOI 10, 8h p.i.), osmotic
783 (lane 4; 80mM KCl, 1h), and arsenite (lane 5; 0.5mM NaAsO₂, 1h) treatment and total protein
784 harvested at the end of the stress period. Quantification of CTD serine 2 (**A**), serine 5 (**B**), and
785 serine 7 (**C**) phosphorylation was performed using the listed antibodies via Western blotting.
786 Phospho-serine levels were normalized to total RPB1 levels and the relative ratio compared
787 to mock-treated samples on the same membrane. Plotted are the means of three biological
788 replicates with standard error with representative Western blots on the right. Statistically
789 significant differences to mock are indicated as * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

790

791 **S2 Fig. CTD serine 7 phosphorylation in cycloheximide reversal and infection with HSV-1**
792 **immediate-early gene mutants.** (A) Human foreskin fibroblast (HFF) cells infected with HSV-
793 1 17syn+ and treated with DMSO, actinomycin D (ActD), cycloheximide (CHX), or
794 cycloheximide reversal (SWAP; 4h CHX followed by 8h ActD) and total protein analysed at 12h
795 p.i. for levels of CTD Ser7 phosphorylation (pS7) and each indicated protein. Samples for total
796 RPB1 were resolved on 3-8% Tris-Acetate gels to better capture lower molecular weight
797 degradation products. (B) HFF cells infected with indicated HSV-1 mutants at MOI 10 for 1h,
798 and inoculum replaced with growth media or media containing phosphonoacetic acid (PAA)
799 for 8h. Total protein was harvested and levels of pS2, pS7, and RPB1 analyzed by Western
800 blotting. Wild-type (WT) strains F, KOS, and 17syn+ are shown next to corresponding mutants

801 for ICP22 (Δ 22), ICP4 (Δ 4), ICP27 (Δ 27), and ICP0 (Δ 0). (C) Quantification of Western blots
802 described in (B). Means of at least three biological replicates for PAA-treated samples are
803 plotted with standard errors. Statistically significant differences to mock are indicated as * p
804 < 0.05, ** p < 0.01.

805

806 **S3 Fig. Proteasome inhibition blocks the loss of CTD serine 2 and serine 7 phosphorylation**
807 **during HSV-1 infection.** Human foreskin fibroblasts were infected with HSV-1 17syn+ at an
808 MOI of 10 and treated with indicated proteasome inhibitors or DMSO vehicle control. After 8
809 hours of treatment, total protein was collected and analysed by Western blotting. (A)
810 Expression of RPB1 (red), phosphorylated CTD Ser2 (pS2, green), vinculin, p53, and HSV-1
811 protein ICP0. Star indicates a high MW band likely corresponding to ubiquitinated RPB1 with
812 arrows indicating accumulated degradation products. (B) Expression of RPB1 (red) and
813 phosphorylated CTD Ser7 (pS7, green) by Western blotting. White lines are the result of
814 cropping irrelevant samples.

815

816 **S4 Fig. Quantification of RPB1 levels after stress using different antibodies.** Human foreskin
817 fibroblasts were subjected to heat (44°C, 2h), HSV-1 infection (strain 17syn+, MOI 10, 8h p.i.),
818 high salt (80mM KCl, 1h), and arsenite (0.5mM NaAsO₂, 1h) treatment and total protein
819 harvested at the end of the stress period. Quantification of RPB1 was performed using the
820 listed antibodies via Western blotting and normalizing to Vinculin levels on the same
821 membrane. Plotted are the means of three biological replicates with standard deviations with
822 representative Western blots to the right.

823

824 **S5 Fig. RPB1 serine CTD phosphorylation and viral replication in HSV-1-infected RPB1**
825 **K1268R cells.** Clonal cell lines D12 and E2 bearing the RPB1 K1268R mutation and parental
826 wild-type (WT) 293T cells were infected with HSV1(17+)-LoxCheVP26 expressing the VP26
827 viral late gene fused to mCherry and harvested at 8h p.i. (A) Representative Western blots of
828 CTD serine phosphorylations from data graphed in Fig 3. (B) Viral gene expression at analyzed
829 timepoints is comparable across cell lines as viewed by live-cell imaging of mCherry-VP26
830 fusion protein. (C) Time-course of HSV-1 strain 17+ production from an initial infection of MOI
831 0.01. Plotted are the means of two replicates with standard deviations. PFU, plaque-forming
832 units; ND, no plaques detected for this timepoint; LOD, statistical limit of detection defined
833 by 10 plaques at lowest dilution.

834

835 **S6 Fig. Comparison of RPB1 levels in the amanitin-based replacement assay.** Cells treated in
836 parallel for the RPB1 replacement assay described in Fig 5 were harvested at the time of
837 infection and probed for total CTD levels, the HA tag from the *trans*-expressed RPB1
838 constructs, and vinculin as a housekeeping gene.

839

840 **S1 Table. Antibodies used in this study.**

841

842 **Figure captions**

843 **Fig 1. Western blot quantification of RPB1 CTD modifications in primary human fibroblasts**
844 **during conditions of polyA-site read-through.**

845 (A) Human foreskin fibroblasts were subjected to heat (44°C, 2h), HSV-1 infection (strain
846 17syn+, MOI 10, 8h), osmotic (80mM KCl, 1h), and oxidative (0.5mM NaAsO₂, 1h) stress and
847 total protein harvested at the end of the stress period. Samples were resolved by SDS-PAGE
848 and probed for levels of RPB1, its CTD modifications, and vinculin as a housekeeping control.
849 Signal for each CTD modification was measured, normalized to the signal for total RPB1 on
850 the same blot, and plotted relative to levels in untreated cells. (B) Mean values of three
851 biological replicates with standard deviations are plotted. Statistically significant differences
852 to mock are indicated as * p < 0.05, ** p < 0.01.

853

854 **Fig 2. Loss of CTD serine 7 phosphorylation in HSV-1 infection requires immediate-early**
855 **proteins ICP22 and ICP27.**

856 (A) Human foreskin fibroblasts (HFF) were infected with HSV-1 17syn+ with and without DNA
857 replication inhibitor phosphonoacetic acid (PAA) and total protein harvested at given
858 timepoints. Levels of CTD serine 7 phosphorylation (pS7) relative to total RPB1 were
859 quantified by Western blotting. (B) Means of at least three replicates relative to the
860 corresponding mock-infected sample plotted with standard deviations. (C) HFF cells infected
861 with HSV-1 KOS treated with PAA or KOS-derived mutants lacking the combinations of
862 immediate-early genes indicated in the table in the bottom right. White bars indicate removal
863 of irrelevant samples. Total protein was harvested at 8h p.i. and pS2/7 levels probed by
864 Western blot. (D) Quantification of phospho-serine normalized to total RPB1. Means of three

865 replicates normalized to mock-infected samples with PAA with standard error are plotted,
866 values from KOS are from PAA-treated samples. Statistically significant differences to mock
867 are indicated as * $p < 0.05$, ** $p < 0.01$.

868

869 **Fig 3. Effects of proteasome inhibitors and RPB1 polyubiquitination mutants on HSV-1-**
870 **induced RPB1 remodeling.**

871 (A) Human foreskin fibroblasts were infected with HSV-1 17syn+ and treated with indicated
872 proteasome inhibitors for 8h before collection of total protein and quantification of CTD Ser2
873 and Ser7 phosphorylation by Western blotting. Plotted are means of two replicates with
874 standard deviations. (B-D) 293T parental wild-type (WT) and clonally derived RPB1 K1268R
875 mutant cell lines were infected with HSV1(17+)-LoxCheVP26 and total RPB1 or
876 phosphorylated CTD serine residues quantified by Western blotting. (B) Relative levels of CTD
877 serine phosphorylation at 8h p.i.; plotted are three individual replicates with longest lines
878 indicating means and shortest standard error ranges. (C) Representative Western blot of RPB1
879 levels in uninfected (Un.) 293T WT and RPB1 K1268R or cells infected for 8 and 24h. (D)
880 Relative RPB1 levels normalized to vinculin in infected 293T WT and RPB1 K1268R cells;
881 plotted are means of at least three replicates with standard error.

882

883 **Fig 4. Co-localization of RPB1 CTD modifications with viral replication compartments.**

884 Human foreskin fibroblasts were infected with HSV-1 strain 17syn+ for 8h before fixation.
885 Antibody staining was performed for viral protein ICP4, RPB1, and its respective CTD
886 modifications. p=phosphorylation, me=methylation.

887

888 **Fig 5. CTD serine 2, but not serine 7, is required for efficient viral gene expression.**

889 HEK-293T cells were co-transfected with a construct expressing Azurite blue fluorescent
890 protein as a transfection marker and plasmids expressing amanitin-resistant RPB1 with wild-
891 type (WT) or indicated mutant CTDs, or the control vector pcDNA3 lacking any polymerase.
892 The next day, α -amanitin was added to degrade endogenous RPB1 for 24h followed by
893 infection with an eYFP-ICP0-/gC-mCherry-expressing HSV-1. Live-cell imaging was performed
894 at 24h p.i. All images were acquired with the same settings, with infection of untransfected,
895 amanitin-untreated cells included as a reference for the relative level of viral gene expression.
896 PC: phase contrast, S2A: serine 2 to alanine, S7A: serine 7 to alanine, S7E: serine 7 to
897 glutamate. Scale bars indicate 100 μ m.

A

bioRxiv preprint doi: <https://doi.org/10.1101/2021.06.28.450160>; this version posted June 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.



**B**

Figure 1




Figure 2







Figure 3




Figure 4




Figure 5